This phase III trial is trying to determine whether it is more effective to use radiotherapy alone or in combination with immunotherapy in patients will non-small cell lung cancer.
This trial is treating patients with non-small cell lung cancer.
This is a radiotherapy and systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)
Eligible patients will be randomised to receive stereotactic body radiotherapy (SBRT) once every 3 days for 3-5 fractions (dependent on tumour type/location; 45-54 Gray total) over approximately 2 weeks PLUS pembrolizumab (200mg) or a placebo (normal saline solution) via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle will run for 21 days.
Recruiting Hospitals Read More